Trial Profile
A Single Center, Open-Label, Non-Randomized, Uncontrolled, Multiple-Dose, Dose Escalation Study of the Safety, Pharmacokinetics, Efficacy and Long Term Safety of HGT-1111 (Recombinant Human Arylsulfatase A [rhASA, Metazym]) for the Treatment of Patients With Late Infantile Metachromatic Leukodystrophy (MLD)
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 07 Aug 2015
Price :
$35
*
At a glance
- Drugs Cerebroside-sulfatase (Primary)
- Indications Metachromatic leukodystrophy
- Focus Therapeutic Use
- Sponsors Shire
- 31 Aug 2018 Biomarkers information updated
- 07 May 2014 New trial record